logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for pharmaceutical industry professionals · Tuesday, April 15, 2025 · 803,603,278 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Pharmaceutical Industry News  •••  Topics  •  Countries  •  U.S. States

Avastin News Monitoring

  • Published on Apr 14, 2025

    FDA Approves Biocon Biologics’ Bevacizumab Biosimilar

    On April 10, 2025, Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a new bevacizumab biosimilar referencing Genentech’s AVASTIN®.  JOBEVNE™ is a recombinant humanized monoclonal …

    Source: JD Supra - California - Neutral
  • Published on Apr 14, 2025

    FDA Approves Avastin Biosimilar Agent, Jobevne

    The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer types. Approval was based on “a comprehensive package of …

    Source: Medscape - Neutral
  • Published on Apr 14, 2025

    Krivak on PARP Inhibitors and Maintenance Therapy in Ovarian Cancer

    Thomas C. Krivak, MD Director, Ovarian Cancer Center of Excellence Gynecologic Oncology Research Cochair, Society of Gynecologic Oncology Research Institute West Penn Hospital Allegheny Health Network Pittsburgh, PA CASE SUMMARY A 67-year-old patient with …

    Source: Targeted Oncology - Pending
  • Published on Apr 14, 2025

    When will gene therapy be ready for patients with age-related macular degeneration?

    Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in elderly populations worldwide, that will affect almost 290 million individuals by 2040 and is projected to increase significantly due to aging demographics.1 Advanced …

    Source: Ophthalmology Times Europe - Pending
  • Published on Apr 11, 2025

    FDA Approves Biocon’s Jobevne, Bevacizumab Biosimilar

    Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has received approval from the U.S. Food and Drug Administration (FDA) for its cancer treatment biosimilar, Jobevne (bevacizumab-nwgd). The approval marks the company’s seventh biosimilar greenlight …

    Source: Pharma Journalist - Neutral
  • Published on Apr 10, 2025

    FDA Approves Avastin Biosimilar Jobevne Across Several Cancer Types

    The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for intravenous use in cancer types including colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical …

    Source: Cure Today - Neutral
  • Published on Apr 11, 2025

    FDA Approves Bevacizumab Biosimilar for Various Cancer Types

    The FDA has approved bevacizumab-nwgd (Jobevne; Biocon Biologics), a biosimilar referencing bevacizumab (Avastin; Genentech) for the treatment of several different types of cancers. This approval marks bevacizumab-nwgd as the sixth reference product to …

    Source: Pharmacy Times - Neutral
  • Published on Apr 10, 2025

    FDA Greenlights Bevacizumab Biosimilar Across Cancer Types

    A new bevacizumab (Avastin) biosimilar, bevacizumab-nwgd (Jobevne), has been approved for the treatment of various cancers. Bevacizumab-nwgd offers a potentially more affordable treatment option. The biosimilar demonstrated comparable efficacy and safety …

    Source: Targeted Oncology - Pending
  • Published on Apr 10, 2025

    FDA Approves Biocon’s Avastin Biosimilar

    The FDA has approved the fifth biosimilar of Genentech’s Avastin (bevacizumab). Biocon Biologics' biosimilar Jobevne (bevacizumab-nwgd), like Avastin and other approved biosimilars, is a recombinant humanized monoclonal antibody used to treat several …

    Source: Managed Healthcare Executive - Neutral
  • Published on Apr 11, 2025

    FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

    Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd), a biosimilar to the reference Avastin (bevacizumab). Jobevne is a recombinant humanised monoclonal antibody which …

    Source: Pharmaceutical Technology - Neutral
  • Published on Apr 11, 2025

    Biocon Biologics secures FDA approval for cancer drug Jobevne 

    The shares of Biocon Biologics Ltd were trading at ₹316.4 up by ₹10.15 or 3.31 per cent on the NSE today at 11 am. Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced that the U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd …

    Source: The Hindu Business Line - Neutral
  • Published on Apr 11, 2025

    Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

    Biocon's share price surged 5.5 percent in intra-day trade on Friday, April 11, after the company’s subsidiary, Biocon Biologics, received approval from the US Food and Drug Administration (USFDA) for JOBEVNE, a biosimilar version of Bevacizumab for …

    Source: Mint - Neutral
  • Published on Apr 11, 2025

    Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug

    Shares of Biocon rallied 5.6% to an intraday high of Rs 322.25 on the BSE on Friday after its subsidiary, Biocon Biologics, announced it had received approval from the U.S. Food and Drug Administration (USFDA) to market Jobevne (bevacizumab-nwgd), a …

    Source: The Economic Times - Pending
  • Published on Apr 10, 2025

    Biocon Biologics obtains FDA nod for Avastin biosimilar

    Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for intravenous use.  Jobevne, which is a recombinant humanized monoclonal antibody used to treat several different types …

    Source: Drug Store News - Pending
  • Published on Apr 10, 2025

    Bevacizumab Biosimilar Granted FDA Approval for Several Cancer Types

    The FDA granted approval to bevacizumab-nwgd (Jobevne), a biosimilar for bevacizumab (Avastin), for indications in several cancer types including colorectal cancer; non-squamous non-small cell lung cancer; glioblastoma; renal cell carcinoma; cervical …

    Source: Oncology Nursing News - Pending
  • Published on Apr 10, 2025

    Biocon Biologics secures USFDA approval for cancer treatment biosimilar

    Biocon Biologics, a subsidiary of Biocon Ltd, announced on Thursday that it has received approval from the United States Food and Drug Administration (USFDA) to market Jobevne (bevacizumab-nwgd), a biosimilar to the oncology drug Avastin (bevacizumab), for …

    Source: Zee Business - Indeterminate
  • Published on Apr 10, 2025

    FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

    The FDA has granted approval to bevacizumab-nwgd (Jobevne)—a biosimilar referencing bevacizumab (Avastin)—for the treatment of patients with a variety of solid tumors, including metastatic colorectal cancer (mCRC); unresectable, locally advanced, recurrent …

    Source: OncLive - Pending
  • Published on Apr 10, 2025

    Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

    Dive Brief: Tempest Therapeutics is seeking a buyer or partner, saying Wednesday it has hired financial advisers to “advance its promising clinical stage programs and maximize stockholder value,” as the California-based biotechnology company prepares a …

    Source: BioPharma Dive - Pending
  • Published on Apr 11, 2025

    Mum issues sunbed warning after TWO bouts of cancer

    A former sunbed user has warned of their dangers after she spent 15 years battling TWO bouts of deadly skin cancer. Caroline Madden, 59, cautioned those tempted by tanning booths about the risks posed by exposure to UV rays following her “horrific” health …

    Source: Stoke-on-Trent Live - Pending

06 days 05:13:47

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more pharmaceuticals news or search news using your own keywords. There are 803,603,278 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country >
Pharmaceutical Industry News by U.S. State >
Pharmaceutical Industry News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 03/19/2025

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Pharmaceutical Industry Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow us on Facebook and connect with us on LinkedIn

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement